Trelagliptin Succinate is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting this enzyme to increase the level of incretin hormones in the body, thereby promoting insulin secretion and lowering blood glucose for the treatment of type 2 diabetes. Its most notable feature is an ultra-long duration of action, allowing for once-weekly oral dosing, which significantly enhances patient convenience and medication adherence.